Neurology · Pain ManagementRegulatory Approvalregulatorymid-term

FDA Accepts Pregabalin Supplement Application ANDA209357 from MSN

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/23/2026, 12:30:33 PM

Assessment confidence: 59% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of the supplemental application for Pregabalin by MSN is a significant regulatory milestone that could enhance MSN's competitive positioning in the pain management market. This development necessitates close monitoring of the approval process and its implications for market dynamics. Regulatory context from FDA (FDA AP — PREGABALIN (SUPPL)) supports the near-term read. Assessment grounded in 6 ranked evidence items (2 high-relevance).

Strategic Assessment

Portfolio teams should assess the implications of this approval on market share and pricing strategies for Pregabalin. The strongest clinical anchor is Pain Management During Panretinal Photocoagulation for Diabetic Retinopathy: Safety and Efficacy of Peribulbar Anesthesia (ClinicalTrials.gov), sub-indication match (pain). In pain, 4 regulatory and 0 competitive items passed relevance filtering for Pregabalin.

Competitive Pressure

The most relevant competitive pressure comes from This acceptance may enhance MSN's position in the pain management market, potentially impacting competitors with similar products..

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — PREGABALIN (SUPPL) (FDA). Entity match (pregabalin); Regulatory pathway relevance (nda). The acceptance of the supplemental application indicates a positive regulatory trajectory, but the final approval status will determine the extent of its impact on market entry and compliance.

Key Risks

Elevated medium regulatory exposure for Pregabalin could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If approved, this could lead to increased market share for MSN, potentially affecting pricing strategies and competitive positioning against other players in the pain management sector.
Portfolio teams should assess the implications of this approval on market share and pricing strategies for Pregabalin.

What Would Change This Assessment

This becomes more urgent if Monitor the review timeline and any subsequent announcements regarding the approval status and market launch.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — PREGABALIN (SUPPL)
FDAmedium relevance
Entity match (pregabalin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PREGABALIN (SUPPL)
FDAmedium relevance
Entity match (pregabalin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PREGABALIN (SUPPL)
FDAmedium relevance
Entity match (pregabalin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PREGABALIN (ORIG)
FDAmedium relevance
Entity match (pregabalin); Regulatory pathway relevance (nda)
FDA document
View source
IND Application Reporting: IND Safety Reports
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Investigational New Drug (IND) Application
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Pain Management During Panretinal Photocoagulation for Diabetic Retinopathy: Safety and Efficacy of Peribulbar Anesthesia
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Effectiveness of Coordinated Care to Reduce the Prolonged Disability Risk Among Patients Suffering From Low Back Pain in Primary Care
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Multiple Micronutrient Supplementation for Maternal Anemia Prevention in Tanzania
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Safety and Efficacy of the BTL-043 and BTL-899 Devices in Alleviating Back Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

FDA Approves Supplemental Application for QTERN (Dapagliflozin/Saxagliptin)
Humanexa Signalslow relevance
Sponsor/company relevance (AstraZeneca)
FDA Grants Priority Review for LEQEMBI Supplement Application
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities
FDA Accepts Application for XOCOVA (Ensitrelvir) by Shionogi
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Effect of transcutaneous auricular vagus nerve stimulation on postoperative pain in patients undergoing thoracoscopic partial lung resection: a randomized, double-blind, controlled clinical trial.
PubMedhigh relevance
Sub-indication match (pain)
FDA document
View source
The dual role of exosomes in renal fibrosis and their potential for clinical translational applications.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Rotation-traction manipulation versus cervical traction for axial neck pain caused by cervical degenerative disc disease: a multicenter randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Immunogenicity and safety of a 2 + 1 schedule of the DTaP-IPV-HB-Hib hexavalent combination vaccine in preterm infants in Spain.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Pregabalin

Commercial impact

medium

If approved, this could lead to increased market share for MSN, potentially affecting pricing strategies and competitive positioning against other players in the pain management sector.

Regulatory impact

medium

The acceptance of the supplemental application indicates a positive regulatory trajectory, but the final approval status will determine the extent of its impact on market entry and compliance.

What to watch

Monitor the review timeline and any subsequent announcements regarding the approval status and market launch.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.